z-logo
Premium
Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older
Author(s) -
Menzies Robert I,
Krause Vicki L,
McIntyre Peter B
Publication year - 2014
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja14.00399
Subject(s) - pneumococcal polysaccharide vaccine , pneumococcal vaccine , medicine , pneumococcal disease , biology , streptococcus pneumoniae , microbiology and biotechnology , antibiotics
Results: The proportion of people aged 65 years who were vaccinated within the previous 5 years in jurisdictions excluding Victoria ranged from 41% to 64% over the study period, with no clear trend over time. Incidence rate ratios in the 65-year age group were 0.11 (95% CI, 0.09–0.14) for 7vPCV serotypes, 1.64 (95% CI, 1.41–1.91) for 23vPPV–non-7vPCV serotypes and 2.07 (95% CI, 1.67– 2.57) for non-23vPPV serotypes. The incidence rate ratio for total IPD was 0.65 (95% CI, 0.59–0.71) for people aged 65 years, and 0.80 (0.71–0.90) for people aged 50–64 years. The estimate of 23vPPV effectiveness was 61.1% (95% CI, 55.1%–66.9%).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom